BVF Inc. IL Boosts Holdings in TScan Therapeutics, Inc. $TCRX

Key Points

• BVF Inc. IL increased its stake in TScan Therapeutics by 63.6%, acquiring an additional 1,900,000 shares, bringing their total ownership to 4,889,474 shares valued at $6,747,000.
• Major hedge funds including Wells Fargo and Wellington Management have also increased their investments in TScan Therapeutics, indicating strong institutional support with 82.83% of shares held by institutional investors.
• TScan Therapeutics recently reported earnings of ($0.28) per share, meeting analyst expectations while generating revenue of $3.08 million, significantly above the consensus estimate of $1.31 million.

BVF Inc. IL increased its position in TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) by 63.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 4,889,474 shares of the company's stock after purchasing an additional 1,900,000 shares during the quarter. BVF Inc. IL owned approximately 8.64% of TScan Therapeutics worth $6,747,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of TCRX. Wells Fargo & Company MN grew its position in shares of TScan Therapeutics by 41.1% during the 4th quarter. Wells Fargo & Company MN now owns 19,540 shares of the company's stock worth $59,000 after purchasing an additional 5,694 shares in the last quarter. Barclays PLC raised its stake in TScan Therapeutics by 16.3% during the fourth quarter. Barclays PLC now owns 67,508 shares of the company's stock worth $206,000 after buying an additional 9,441 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in TScan Therapeutics by 108.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 280,028 shares of the company's stock valued at $851,000 after purchasing an additional 145,731 shares in the last quarter. Stifel Financial Corp increased its position in shares of TScan Therapeutics by 10.7% during the fourth quarter. Stifel Financial Corp now owns 109,700 shares of the company's stock worth $333,000 after acquiring an additional 10,567 shares in the last quarter. Finally, BNP Paribas Financial Markets purchased a new position in TScan Therapeutics during the fourth quarter worth about $198,000. Institutional investors and hedge funds own 82.83% of the company's stock.

TScan Therapeutics Trading Up 1.1%

NASDAQ TCRX traded up $0.02 during trading on Friday, hitting $1.91. The company had a trading volume of 270,203 shares, compared to its average volume of 195,354. The company has a current ratio of 7.06, a quick ratio of 7.06 and a debt-to-equity ratio of 0.18. TScan Therapeutics, Inc. has a one year low of $1.02 and a one year high of $6.23. The company has a market cap of $108.39 million, a price-to-earnings ratio of -1.75 and a beta of 1.00. The company's fifty day moving average is $1.76 and its 200-day moving average is $1.62.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.28). The company had revenue of $3.08 million during the quarter, compared to analyst estimates of $1.31 million. TScan Therapeutics had a negative net margin of 1,964.88% and a negative return on equity of 63.33%. On average, sell-side analysts predict that TScan Therapeutics, Inc. will post -1.12 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on TCRX shares. Wedbush reiterated an "outperform" rating and issued a $7.00 target price on shares of TScan Therapeutics in a research note on Tuesday, August 12th. Wall Street Zen raised shares of TScan Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, July 12th. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $7.80.

TScan Therapeutics Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.